Kazia Therapeutics Ltd ADR
Yahoo Finance • 20 hours ago
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in Cancer SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company develop... Full story
Yahoo Finance • 3 months ago
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
SYDNEY, July 28, 2026 (GLOBE NEWSWIRE) -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resista... Full story
Yahoo Finance • 10 months ago
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stag... Full story
- IXIC
Mentioned:
Yahoo Finance • 12 months ago
Nuclear Power Surge, $10M Buyback, and a $1.9B SEO Bombshell
DENVER, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Investors are digesting major developments across the energy, tech, oncology, and entertainment sectors. Nuclear Power Roars Back: DOE Backs Constellation’s Crane Clean Energy Center Constella... Full story
Yahoo Finance • last year
Discover the top movers in Thursday's pre-market session.
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT YYGH [https://www.chartmill... Full story
Yahoo Finance • 3 years ago
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
SYDNEY, July 6, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that its lead program, paxalisib, has been awarded Fast Track Designation (FTD)... Full story
Yahoo Finance • 4 years ago
KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING
SYDNEY, April 4, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data for both of its pipeline molecules, paxalisib and... Full story
Yahoo Finance • 4 years ago
Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More Shares
Those following along with Kazia Therapeutics Limited (ASX:KZA) will no doubt be intrigued by the recent purchase of shares by insider Stephen Abolakian, who spent a stonking AU$1m on stock at an average price of AU$0.12. That purchase boo... Full story
Yahoo Finance • 4 years ago
Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies
LONDON, UK / ACCESSWRE / December 19, 2022 / Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research center) to investigate the utility of its lead asset,... Full story
Yahoo Finance • 4 years ago
Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
LONDON, UK / ACCESSWIRE / November 2, 2022 / Kazia Therapeutics' Q123 cash flow report provided an update on the company's financial position and business progress. While the quarter was dominated by lead asset paxalisib hitting a roadbloc... Full story
Yahoo Finance • 4 years ago
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Dr... Full story
Yahoo Finance • 4 years ago
KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE
SYDNEY, May 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this di... Full story